Massive study: Merck's diabetes mega-blockbuster doesn't increase heart failure risk

Results from TECOS, which included more than 14,000 patients, showed no increased risk of heart problems in general.

By Nicole Gray • June 11, 2015

Biosim war heats up as Merck's Remicade & Enbrel biosimilars bag major wins in RA

The pharma giant and Samsung Bioepis are collaborating on biosimilars of five of the top-selling drugs in the world.

By Sy Mukherjee • June 10, 2015

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Lilly's Trulicity and Novo's IDegLira best Lantus in trials

The double-whammy might be of concern to Sanofi.

By Nicole Gray • June 9, 2015

Massive new study: The statin-memory lapse connection may be unfounded

That would be great news for millions of patients.

By Nicole Gray • June 9, 2015

Titan Pharma's opioid addiction implant shows promise in phase III

After a 2013 rejection by the FDA, the company and its partner Braeburn Pharmaceuticals are giving Probuphine another go.

By Sy Mukherjee • June 8, 2015

Report: Metformin decreases glaucoma risk in older adults

A daily 1.5-gram dose of metformin over two years decreased the risk of glaucoma by 25% in diabetics.

By Nicole Gray • June 5, 2015

NCI launching largest-ever personalized medicine study for cancer drugs

The effort aims to match mutations with existing drugs.

By Nicole Gray • June 3, 2015

A final ASCO15 roundup: Docs slam prices for meds, ImmunoGen eyes redemption, Puma gets hammered

The massive annual oncology meeting is coming to a close. Here's what you need to know. 

By Sy Mukherjee • June 2, 2015

ASCO15: BMS' new standard for melanoma, Celldex's brain cancer vax, Clovis' ovarian cancer win

The data deluge continued on ASCO Sunday, with a lot of promising news from large and smaller companies alike. Here's what you need to know.

By Sy Mukherjee • May 31, 2015

Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J

The American Society of Clinical Oncology mega-conference started off with a bang this weekend. Here are the ups, downs, and most important developments you need to know about.

By Sy Mukherjee • May 30, 2015

New evidence-based consensus: Start HIV treatment at diagnosis

In a trial, newly diagnosed HIV patients who started treatment immediately were 53% less likely to develop AIDS or die. 

By Nicole Gray • May 29, 2015

Otonomy's inner-ear drug flops in trials

The company has been developing OTO-104 for treatment of Meniere's disease, which leads to deafness, vertigo, and ringing in the ears.

By Nicole Gray • May 22, 2015

Sanofi/Regeneron's arthritis drug nails it in phase III

A regulatory filing is expected in Q4 of this year.

By Nicole Gray • May 22, 2015

Bluebird shares more data on its breakthrough gene therapy trials, and it continues to impress

The sample size is still small. But patients with beta-thalassemia and severe sickle cell disease are responding quite well to the treatment with no adverse effects so far.

By Sy Mukherjee • May 22, 2015

Study: Tylenol use during pregnancy may lower testosterone in male offspring

But some are warning to take the study with a grain of salt, as it was conducted in mice.

By Nicole Gray • May 21, 2015

GW Pharma moves CEO to US to lay groundwork for cannabis-epilepsy med approval

Justin Gover is moving from London, where GW is headquartered, to Southern California. And the company's riding high off results from an epilepsy trial.

By Nicole Gray • May 20, 2015

Sanofi/Regeneron reports glowing phase 2b results for versatile asthma hopeful

Earlier this year, Sanofi EVP Pascale Witz told BioPharma Dive that dupilumab was one of the company's most exciting in-development products thanks to its potential in multiple, diverse therapeutic categories.

By Nicole Gray • May 20, 2015

Bluebird cuts deal with regulators, plots path to first-ever US gene therapy approval

The biotech's gene therapy LentiGlobin for beta-thalassemia will have an accelerated approval pathway in the U.S. and Europe. 

By Sy Mukherjee • May 19, 2015

Amgen boasts promising phase II results for migraine drug

But the candidate would enter a busy therapeutic field.

By Nicole Gray • May 18, 2015

Hotly anticipated AZ lung cancer combo effective, but side effects remain a problem

The British pharma giant will be unveiling full data during the American Society of Clinical Oncology (ASCO) conference at the end of May.

By Nicole Gray • May 15, 2015

A preview of the new lung cancer data Roche will debut at ASCO

At the end of this month, attendees of the major oncology conference will be able to learn more about trials involving the PD-L1 inhibitor MPDL3280A.

By Nicole Gray • May 15, 2015

UPDATE: Takeda threatens to break off Orexigen collab after Contrave data drama

Orexigen is defending itself after the Cleveland Clinic released trial results contradicting the firm's heart safety claims (without permission). But now it's facing even more hurdles surrounding its obesity med.

By Sy Mukherjee • May 13, 2015

How do you test an Ebola vaccine when almost no one has Ebola?

Liberia has been declared Ebola-free and there are only a handful of cases in Guinea and Sierra Leone.

By Nicole Gray • May 13, 2015

Study: Measles vax may protect against other infections

The protective effect can last for up to three years, according to researchers.

By Nicole Gray • May 8, 2015

Congress calls for gender equity in clinical trials

Proposed legislation also aims to ensure that drugs approved through an expedited approval pathway are safe and effective for women.

By Nicole Gray • May 7, 2015